About: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
Creator	Zhang, Jun Li, Jinxiu Liu, Lei Liu, Yingxia Wang, Fuxiang Wang, Zhaoqin Yuan, Jing Zhang, Zheng Liu, Wei Li, Zhiyong Wang, Haiyan Su, Yingying Xia, Ningshao Wang, Xin Liao, Xuejiao Qian, Shen He, Bin Yuan, Quan Zhang, Zhao, Juanjuan Ge, Shengxiang Hong, Congming He, Qing Li, Tingdong Sheng-Xiang Ge, Zhang, Tianying
Source	MedRxiv
abstract	Summary Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed. Findings Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006). Interpretation The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.
has issue date	2020-03-03(xsd:dateTime)
bibo:doi	10.1101/2020.03.02.20030189
has license	medrxiv
sha1sum (hex)	ff067164497bcfbd9145be223dcd2b05f159dd63
schema:url	https://doi.org/10.1101/2020.03.02.20030189
resource representing a document's title	Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
resource representing a document's body	covid:ff067164497bcfbd9145be223dcd2b05f159dd63#body_text
is schema:about of	named entity 'RESPONSES' named entity 'antibody testing' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' covid:arg/ff067164497bcfbd9145be223dcd2b05f159dd63 named entity 'UNKNOWN' named entity 'BACKGROUND' named entity 'TITLE' named entity 'LARGELY' named entity 'DEMONSTRATED' named entity 'INFECTED' named entity 'ANTIBODY RESPONSE' named entity 'VIRUS' named entity 'HAVE' named entity 'CORONAVIRUS SARS' named entity 'ANTIBODY TESTING' named entity 'NEWLY' named entity 'SARS-COV-2' named entity 'PATIENTS' named entity 'ANTIBODY' named entity 'SUMMARY' named entity 'VALUES' named entity 'PATIENT' named entity 'CLINICAL' named entity 'FULLY' named entity 'NOVEL CORONAVIRUS' named entity 'SARS-COV-2' named entity 'IS A' named entity 'COVID-19' named entity 'Title' named entity 'responses' named entity 'patients' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'Antibody' named entity 'antibody response' named entity 'COVID' named entity 'coronavirus' named entity 'antibody testing' named entity 'emerging virus' named entity 'Antibody' named entity 'demonstrated' named entity 'emerging' named entity 'antibody' named entity 'responses' named entity 'REMAINS' named entity 'infected' named entity 'Antibody' named entity 'Title' named entity 'Antibody' named entity 'patients' named entity 'virus' named entity 'patient' named entity 'coronavirus' named entity 'Brief' named entity 'BRIEF TITLE' nodeID://b56439534

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software